Table 2.
Current hormone therapy regimens for transgender adults
| Regimen | Typical dose range(s) |
|---|---|
| Testosterone treatment | |
| Injectable (short‐acting: cypionate, enanthate; long‐acting: undecanoate) | 50–100 mg weekly (or 100–200 mg every 2 weeks) |
| 1,000 mg every 12 weeks a (or 750 mg every 4 weeks (initial) then every 10 weeks) | |
| Patches, gel | 2.5–7.5 mg/daily (patches); 50–100 mg daily (gel) |
| Estrogen treatment | |
| Oral tablets: micronized estradiol, estradiol valerate a | 1–8 mg daily, total (divided) |
| Estradiol patches, gel a | 25–200 mcg/daily 1–2 times weekly (patch); 1–2 mg daily (gel) |
| Injectable (estradiol valerate or cypionate) | 2–10 mg weekly (or 5–30 mg every 2 weeks) |
| Adjunctive agents | |
| Cyproterone acetate a | 25–50 mg daily |
| Spironolactone tablets | 100–400 mg daily, total (divided) |
| GnRH agonists | 3.75 mg monthly or 11.25 mg every 3 months (leuprolide acetate); 3.6 mg monthly (goserelin acetate) |